Sandoz Group said it would pay $275 million to settle claims from some plaintiffs in a generics drug pricing antitrust lawsuit in the U.S. The Swiss generics-medicine company said Tuesday that it ...

Sandoz hasn't given a timeline for a regulatory ... Taken alongside Prolia/Xgeva, the brands account for well over 40% of Amgen's current revenues. Other companies working on biosimilar versions ...

Swiss generic medicines firm Sandoz on Tuesday said it had reached a $275 million settlement with plaintiffs in a legacy US generic drug antitrust lawsuit. Sandoz and subsidiary Fougera ...

Sandoz’ Prolia and Xgeva biosimilars – respectively called Jubbonti and Wyost – have been approved for all of the indications of Amgen’s brands and, according to the company, are fully ...

Richard Saynor wants to transform Sandoz Group AG into a world champion in copying leading-edge drugs, including anti-obesity and biological treatments, with the goal of bringing them to the masses.

(RTTNews) - Sandoz Group AG (SDZNY), a Swiss generic and biosimilar medicines maker, announced Tuesday that it has agreed to pay $275 million to the class of end payer plaintiffs to resolve legacy ...

Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) One of several biosimilar value drivers for Sandoz Sandoz remains ...